The application of anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) agents has greatly benefited cancer patients and achieved satisfactory outcomes in clinical practice. Here, CTLA4 is linked to cancer.